Why I’d buy AstraZeneca plc and Taylor Wimpey plc today

Harvey Jones reckons AstraZeneca plc (LON: AZN) and Taylor Wimpey plc (LON: TW) are two of the most tempting plays on the FTSE 100.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Both the pharmaceutical and house building sectors have had a bumpy ride lately, but I still reckon you should buckle up and get on board. In fact, you could even turn recent turbulence to your advantage.

Time to buy

 Today could be a good entry point for AstraZeneca (LSE: AZN) and Taylor Wimpey (LSE: TW), with both seeing their share prices fall by more than 5% in the last three months.

As I wrote last November, investors have to be patient with AstraZeneca right now and put their faith in CEO Pascal Soriot’s long-term drugs pipeline. That remains the case following yesterday’s publication of the group’s full-year 2017 results, which did little to move the share price either way… because the prize is further down the line. AstraZeneca is positioned for product sales growth in full-year 2018, which would be the first time in four years, but the real action should come in 2019 and beyond, when we see whether current R&D finally bears fruit.

Income play

You can find more detail on yesterday’s results in this piece by my Foolish friend Kevin Godbold, but what impresses me is how investors have kept their faith in the AstraZeneca. It still trades 15% higher than a year ago, and investors continue to put a premium on its prospects, with the stock trading on a forward valuation of 19.1 times earnings. That’s despite the anticipated 5% drop in earnings per share (EPS) in 2018.

City analysts expect better news in 2019, when they are pencilling in 12% EPS growth. A forecast yield of 4.3% should keep spirits up while investors wait to see if Soriot can deliver. We will know more in the second half of this year, when the results of several high-profile pipeline treatments are in.

Full house

House builders were hammered in the wake of Brexit, which always struck me as an over-reaction. Latest figures from Nationwide show house prices rising 3.2% in the year to January, which is more than respectable and should soothe fears that we are nearing the top of the property market.

Last month, Taylor Wimpey said it anticipates further growth and improved performance in 2018, despite ongoing political and economic uncertainty. Average selling prices on private completions rose 3% to £296,000, with the overall average selling price up 4% to £264,000.

Taylor-made

Taylor Wimpey’s growth prospects are solid but the income stream is spectacular, with a forecast yield of 7.6%, covered 1.4 times, making this one of the best on the FTSE 100. Management has pledged to pay a total full-year 2018 dividend of around £500m, subject to shareholder approvals, with further capital returns in 2019 and beyond.

The £6.19bn company’s earnings may slow after four years of double-digit EPS growth.

However, forecasters are pencilling in steady single-digit growth of 9% and 4% in 2018 and 2019, respectively, by which time the stock will still be yielding a dizzying 7.8%. The yield alone makes this is one of the most attractive companies on the FTSE 100, while a forecast valuation of a mere 9.5 times earnings seals the deal.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »